Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Whatever you're prescribed, keeping a consistent record makes every conversation with your prescriber more informed
It is important to note that there is no established direct causative mechanism linking GLP-1 receptor activation to increased gastric acid production or lower esophageal sphincter dysfunction
Yes, and this is a common strategy
In the 64-week OASIS 4 clinical trial: 6.9% of patients treated with once-daily Wegovy pill 25 mg and 5.9% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions 1 The most common event type leading to discontinuation was gastrointestinal adverse reactions: 3.4% for Wegovy pill vs 2.0% for placebo 1 The most common adverse reactions leading to discontinuation (frequency 1%) were: nausea (1.5% vs 0%) and sleep disorder (1% and 0%) for the Wegovy pill and placebo 3 GI adverse reactions were generally transient and most prevalent during the dose-escalation period 3 Median duration of nausea: 13 days for patients on the Wegovy pill vs 12 days for patients on placebo Median duration of vomiting: 2 days for patients on the Wegovy pill vs 1 day for patients on placebo Median duration of diarrhea: 4 days for patients on the Wegovy pill vs 4 days for patients on placebo Median duration of constipation: 26 days for patients on the Wegovy pill vs 127 days for patients on placebo No limitations of use in patients with hepatic impairment No clinically significant differences in semaglutide pharmacokinetics based on renal impairment or mild, moderate, or severe hepatic impairment Frequently Asked Questions: Wegovy Pill Safety Nausea is the most common side effect of the Wegovy pill
